Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients

Respiratory Research

Lieven Joseph Dupont¹  Sven Seys³  Ann Decraene³  Hans Scheers³  Pieter Christian Goeminne² 

[1] Department of Respiratory Medicine, University Hospital Gasthuisberg, Leuven, Belgium;Department of Respiratory Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium;Laboratory of Pneumology, Katholieke Universiteit Leuven, Leuven, Belgium

关键词: Risk factor;    Morbidity;    Mortality;    Non-cystic fibrosis;    Bronchiectasis;   

Others  :  796741
DOI  :  10.1186/1465-9921-13-21

 received in 2011-12-23, accepted in 2012-03-16,  发布年份 2012

【 摘 要 】

Introduction

There is a relative lack of information about the death rate and morbidity of non-cystic fibrosis bronchiectasis and most studies are limited due to referral bias. We wanted to assess death rate and morbidity in those patients at our hospital.

Methods

Adult patients seen at our department between June 2006 and November 2009 were recruited if the key string "bronchiect-" was mentioned in electronic clinical records and if chest CT imaging was available. Clinical records of all patients with confirmed radiologic diagnosis of bronchiectasis were reviewed and clinical characteristics were analyzed.

Results

539 patients with a radiographic diagnosis of non-cystic fibrosis bronchiectasis were identified in a retrospective cross-sectional analysis giving a prevalence of 2.6% in our hospital population. A wide range of etiologies was found with idiopathic bronchiectasis in 26%. In the 41 months interval, 57 patients (10.6%) died. We found a median exacerbation rate of 1.94 per year. Bacterial colonization status was associated with more deaths, exacerbation rate, symptoms and reduced pulmonary function. Pulmonary hypertension was found in 48% of our patients.

Conclusions

We evaluated a large non-cystic fibrosis bronchiectasis population, and provided new epidemiological data on associations between clinical characteristics and deaths and morbidity in these patients.

【 授权许可】

   
2012 Goeminne et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Bilton D: Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med 2008, 14:595-599.
• [2]Roguin A: Rene Theophile Hyacinthe Laennec (1781-1826): the man behind the stethoscope. Clin Med Res 2006, 4:230-235.
• [3]Shah RM, Sexauer W, Ostrum BJ, Fiel SB, Friedman AC: High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR Am J Roentgenol 1997, 169:375-380.
• [4]Goeminne P, Dupont L: Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010, 86:493-501.
• [5]Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, Flower CD, Bilton D, Keogan MT: An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000, 162:1277-1284.
• [6]Shoemark A, Ozerovitch L, Wilson R: Aetiology in adult patients with bronchiectasis. Respir Med 2007, 101:1163-1170.
• [7]Angrill J, Agusti C, de Celis R, Rano A, Gonzalez J, Sole T, Xaubet A, Rodriguez-Roisin R, Torres A: Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002, 57:15-19.
• [8]King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW: Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007, 101:1633-1638.
• [9]Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J: Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132:1565-1572.
• [10]Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT: Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34:125-131.
• [11]Murray MP, Pentland JL, Turnbull K, MacQuarrie S, Hill AT: Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34:361-364.
• [12]Tsang KW, Chan WM, Ho PL, Chan K, Lam WK, Ip MS: A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. Eur Respir J 1999, 14:1206-1209.
• [13]Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Dowling RB, Cole PJ, Wilson R: Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998, 12:820-824.
• [14]Brody AS, Klein JS, Molina PL, Quan J, Bean JA, Wilmott RW: High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004, 145:32-38.
• [15]Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009, 30:2493-2537.
• [16]MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J: Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26:720-735.
• [17]Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: General considerations for lung function testing. Eur Respir J 2005, 26:153-161.
• [18]Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
• [19]Chang AB, Grimwood K, Mulholland EK, Torzillo PJ: Bronchiectasis in indigenous children in remote Australian communities. Med J Aust 2002, 177:200-204.
• [20]Singleton R, Morris A, Redding G, Poll J, Holck P, Martinez P, Kruse D, Bulkow LR, Petersen KM, Lewis C: Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000, 29:182-187.
• [21]Twiss J, Metcalfe R, Edwards E, Byrnes C: New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child 2005, 90:737-740.
• [22]Eastham KM, Fall AJ, Mitchell L, Spencer DA: The need to redefine non-cystic fibrosis bronchiectasis in childhood. Thorax 2004, 59:324-327.
• [23]Tsang KW, Tipoe GL: Bronchiectasis: not an orphan disease in the East. Int J Tuberc Lung Dis 2004, 8:691-702.
• [24]Saynajakangas O, Keistinen T, Tuuponen T, Kivela SL: Evaluation of the incidence and age distribution of bronchiectasis from the Finnish hospital discharge register. Cent Eur J Public Health 1998, 6:235-237.
• [25]Morrissey BM, Harper RW: Bronchiectasis: sex and gender considerations. Clin Chest Med 2004, 25:361-372.
• [26]Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R: Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009, 34:843-849.
• [27]Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM: CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995, 165:261-267.
• [28]King P, Bennett-Wood V, Hutchinson P, Robins-Browne R, Holmes P, Freezer N, Holdsworth S: Bactericidal activity of neutrophils with reduced oxidative burst from adults with bronchiectasis. APMIS 2009, 117:133-139.
• [29]Redding GJ, Kishioka C, Martinez P, Rubin BK: Physical and transport properties of sputum from children with idiopathic bronchiectasis. Chest 2008, 134:1129-1134.
• [30]O'Donnell AE, Barker AF, Ilowite JS, Fick RB: Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998, 113:1329-1334.
• [31]Tzortzaki EG, Dimakou K, Neofytou E, Tsikritsaki K, Samara K, Avgousti M, Amargianitakis V, Gousiou A, Menikou S, Siafakas NM: Oxidative DNA damage and somatic mutations: a link to the molecular pathogenesis of chronic inflammatory airway diseases. Chest 2011, in press.
• [32]Wall C, Hoyle JC: Observations on dry bronchiectasis. Br Med J 1933, 1:597-620.
• [33]Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R: Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997, 156:536-541.
• [34]Alzeer AH, Al-Mobeirek AF, Al-Otair HA, Elzamzamy UA, Joherjy IA, Shaffi AS: Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis. Chest 2008, 133:468-473.
• [35]Pappalettera M, Aliberti S, Castellotti P, Ruvolo L, Giunta V, Blasi F: Bronchiectasis: an update. Clin Respir J 2009, 3:126-134.
• [36]Montella S, Santamaria F, Salvatore M, Pignata C, Maglione M, Iacotucci P, Mollica C: Assessment of chest high-field magnetic resonance imaging in children and young adults with noncystic fibrosis chronic lung disease: comparison to high-resolution computed tomography and correlation with pulmonary function. Invest Radiol 2009, 44:532-538.
• [37]Dhar R, Anwar GA, Bourke SC, Doherty L, Middleton P, Ward C, Rutherford RM: Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010, 65:553.